(Q40251398)

18 September 2017

title

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors (English)

1 reference

18 September 2017

1 reference

Thomas RK

1

1 reference

18 September 2017

Greulich H

2

1 reference

18 September 2017

Yuza Y

3

1 reference

18 September 2017

Lee JC

4

1 reference

18 September 2017

Tengs T

5

1 reference

18 September 2017

Feng W

6

1 reference

18 September 2017

Chen TH

7

1 reference

18 September 2017

Nickerson E

8

1 reference

18 September 2017

Simons J

9

1 reference

18 September 2017

Egholm M

10

1 reference

18 September 2017

Rothberg JM

11

1 reference

18 September 2017

Sellers WR

12

1 reference

18 September 2017

Meyerson ML

13

1 reference

18 September 2017

publication date

1 January 2005

1 reference

Cold Spring Harbor Symposia on Quantitative Biology

18 September 2017

published in

1 reference

18 September 2017

volume

70

1 reference

18 September 2017

page(s)

73-81

1 reference

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

The new World Health Organization classification of lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Development of the epidermal growth factor receptor inhibitor OSI-774.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Initial sequencing and analysis of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Searching for genetic determinants in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

BRAF as a potential therapeutic target in melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.056

21 January 2018

Identifiers

DOI

10.1101/SQB.2005.70.056

1 reference

18 September 2017

1 reference